140DAO84010模块备件

140DAO84000

应更新指南
正在进行的临床指南1
.
负责更新
技术评估通过尼斯
临床指南计划。一旦
该技术发布了指南
评估将被撤销。
请注意，此选项不保留
与正面相关的资金方向
在一个不错的技术中推荐
评价然而，如果
建议与
技术鉴定
评估可以留在原地（有效
与合并相同）。
不
该指南仍然具有相关性
并且不需要更新。
该指南将在其
当前表单，除非NICE意识到
实质性信息，其中：
让它重新考虑。
对
指导方针应当是：
撤回
该指南不再相关，并且
更新现有建议
不会给NHS增加价值。
指南将被撤销，任何
与正面相关的资金方向
建议将不予保留。
不
1.
关于NICE标准的信息，允许在正在进行的临床指南中进行技术评估
可参见《技术评估流程指南》第6.20节。
©NICE 2021。保留所有权利。以权利通知为准。第8页，共9页
附录C
相关研究所工作
出版
培溴利珠单抗治疗复发或难治性经典霍奇金淋巴瘤
（2018）NICE技术评估指南540。
Nivolumab治疗复发或难治性经典霍奇金淋巴瘤（2017））
尼斯技术评估指南462。
进行中
培溴利珠单抗治疗复发或难治性经典霍奇金淋巴瘤
干细胞移植或至少1次先前治疗。尼斯技术评估指导。
预计2021 6月出版。
《上市许可证》变更详情
技术
原始评估中考虑的营销授权和价格
Brentuximab vedotin（Adcetris）用于治疗复发或难治性
成人CD30阳性霍奇金淋巴瘤：
•自体干细胞移植后，或
•当自体干细胞移植或
多药化疗不是一种治疗选择
•自体干细胞移植后复发或进展的风险增加
移植
活性成分尺寸NHS指示性
价格
布伦图昔单抗韦多汀50 mg 1£2500.00
©尼斯2021。一切正常

140DAO84000

140DAO84000

 guidance should be updated
in an on-going clinical guideline1
.
Responsibility for the updating the
technology appraisal passes to the NICE
Clinical Guidelines programme. Once the
guideline is published the technology
appraisal will be withdrawn.
Note that this option does not preserve the
funding direction associated with a positive
recommendation in a NICE Technology
Appraisal. However, if the
recommendations are unchanged from the
technology appraisal, the technology
appraisal can be left in place (effectively
the same as incorporation).
No
The guidance remains relevant
and an update is not needed.
The guidance will remain in place, in its
current form, unless NICE becomes aware
of substantive information which would
make it reconsider.
Yes
The guidance should be
withdrawn
The guidance is no longer relevant and an
update of the existing recommendations
would not add value to the NHS.
The guidance will be stood down and any
funding direction associated with a positive
recommendation will not be preserved.
No
1
Information on the criteria for NICE allowing a technology appraisal in an ongoing clinical guideline
can be found in section 6.20 of the guide to the processes of technology appraisal.
© NICE 2021. All rights reserved. Subject to Notice of rights. 8 of 9
Appendix C
Relevant Institute work
Published
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
(2018) NICE technology appraisal guidance 540.
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (2017) )
NICE technology appraisal guidance 462.
In progress
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after
stem cell transplant or at least 1 prior therapy. NICE technology appraisal guidance.
Publication expected June 2021.
Details of changes to the marketing authorisation for the
technology
Marketing authorisation and price considered in original appraisal
Brentuximab vedotin (Adcetris) is indicated for treating relapsed or refractory
CD30-positive Hodgkin lymphoma in adults:
• after autologous stem cell transplant or
• after at least 2 prior therapies when autologous stem cell transplant or
multi-agent chemotherapy is not a treatment option
• at increased risk of relapse or progression after autologous stem cell
transplant.
Active ingredients Size NHS indicative
price
Brentuximab vedotin 50 mg 1 £2500.00
© NICE 2021. All righ